🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re thrilled to welcome Thomas Storey to the UKI2S team! Recently joining as a Senior Associate in Future Planet Capital, Thomas brings a wealth of knowledge in both the technical and commercial sides of the space sector. From engineering at Surrey Satellites to developing defence

NK:IO is leading the charge in cancer treatment innovation with their groundbreaking Natural Killer (NK) cell platform, with a little help from UKI2S. Their cutting-edge technology harnesses the power of the immune system to target solid tumours, using a proprietary small

Congrats to our portfolio company, @smartgreenship on being featured on Sky News covering the future of sustainable maritime transpor! 🚢 Their transformational FastRig system, a retractable, rigid sail designed to cut fuel consumption and reduce greenhouse gas emissions is now

Investing in early-stage technologies means investing in our security. 🔑 At SecureX 2.0, Adrian Jones, Venture Partner, spoke about the vital role of venture capital in strengthening national defence capabilities. His message was clear: innovation is our strongest line of

🎉 Huge congrats to iFast Diagnostics on their €5.9M seed round! Their high-speed AST tech, which uses microchip analysis to deliver targeted antibiotic results in under 3 hours is set to help doctors treat infections faster and save lives. We’re proud to be a part of their

🌟 We’re driven by our mission to support organisations tackling global challenges. Our investment in Ikarovec reflects our belief in their incredible research and technology, aiming to treat major causes of blindness through gene therapies. Their bicistronic gene therapy

🔬 Proud to support our portfolio company, Ikarovec, as they take a major step forward in the fight against blindness! 🎉 Ikarovec’s pioneering bicistronic gene therapy program, IKC159V, aims to address geographic atrophy, a leading cause of blindness worldwide. Their solution

Exciting News from Antiverse! We are proud to announce that Antiverse, a techbio company revolutionising antibody design, has raised £7.2M to advance its AI-powered platform targeting G-protein-coupled receptors (GPCRs) and ion channels. These targets have remained a

NK:IO is tackling one of the toughest challenges in oncology: manufacturing clinical-grade NK cells at scale. With their revolutionary technology and a recent £5.9m funding boost, they’re poised to advance their NK cell platform, targeting critical milestones in the fight against

Every second counts in the fight against antimicrobial resistance (AMR), and traditional testing can take up to 72 hours to deliver results. 🕐 Thanks to iFast Diagnostics, this is changing. Their groundbreaking AST platform can provide critical, targeted results in less than 3

From research to real-world impact, iFast Diagnostics is on a mission to revolutionise antimicrobial susceptibility testing. With investment from UKI2S and strategic partnerships, iFAST has developed a rapid testing platform that saves lives by accelerating the right antibiotic

At UKI2S, we have cultivated a dedicated portfolio aimed at boosting early-stage organisations that hold the potential to revolutionise defence and security. Through this support, we're empowering our defence services. Find out more 👇 🔗 ukinnovationscienceseedfund.pulse.ly/zlfjzgp4zx #Investment

With UKI2S investment, twig were able to create their technical proof of concept. twig are creating incredible change, developing sustainable materials using engineering biology. This has a huge impact on the future of green production, as these were materials that have been

💡 Our support not only enabled iFAST to raise £5m but also helped them develop technology that could save countless lives. Discover how our strategic guidance is accelerating advancements in combating AMR 👇 🔗 ukinnovationscienceseedfund.pulse.ly/kqo5wb5azk #Startups #Healthcare #Investment

Huge congratulations to Tokamak Energy on their $52 million upgrade programme for their ST40 spherical tokamak ✨ In collaboration with the U.S. Department of Energy and the UK's Department for Energy Security and Net Zero, they’re driving innovation with the implementation of lithium PFCs. This is a major leap forward in

We’re proud to stand behind Antiverse, a company using AI to develop life-changing therapies for some of the hardest-to-target conditions, such as oncology and cardiovascular diseases. With £600,000 from UKI2S and £7.2m raised overall, Antiverse is poised to transform drug

Shruti Iyengar, Investment Manager at UKI2S, attended the Economist Space Summit in Lisbon earlier this month. Whilst discussing the investment landscape in space technologies, she touched on the key areas that start-ups need to consider when pitching for investment… 👉 Spend

At UKI2S, we're driven by a mission to create lasting impact by backing businesses that redefine our future ✨ Here’s a snapshot of the impact we’ve made: 🔹 Over 1,100 jobs created 🔹 Portfolio companies valued at £1bn+ collectively 🔹 Secured over £730m in co-investment 🔹

Looking to secure investment in 2025? Hear CEO Amanda Smith, from our portfolio company, Pencil Biosciences, as she shares top tips for pitching success 🎤 From planning ahead to staying agile and refining your approach, mastering the art of the pitch is key to standing out.

Thank you so much to our team, partners, and portfolio organisations who made 2024 our best year yet ✨ This year we welcomed 11 new companies to our portfolio, backed 14 portfolio companies again with follow-up funding, hosted a number of successful events including Knowledge